Syros Pharmaceuticals Inc SY-1425 in Newly Diagnosed HR-MDS - Corporate Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Syros Pharmaceuticals KOL event on the potential for SY-1425 and]the newly diagnostic higher-risk MDS. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Dr. Nancy Simonian with Syros Pharmaceuticals. You may begin.
Thank you. Welcome to our KOL investor event on SY-1425 in higher-risk MDS. We will be making forward-looking statements. For a full description of our risk factors, you can go on to our website.
Slide 3. Today's webcast is the first of a 3-part series on our hematology portfolio. I hope you can also join us for our June event on unfit AML and our July event on APL.
Moving to Slide 4. For today's agenda, I will start with a brief corporate overview. And then we are excited to have Dr. Amy DeZern, the Director of the Bone Marrow Failure and MDS Program, an
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
